

Infectious Disease Therapeutics Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti-bacterial, Anti-fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

Market Report | 2024-01-25 | 193 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$5190.00
- Site Price \$7190.00
- Enterprise Price \$9190.00

Report description:

The infectious disease therapeutics market was valued at US\$ 119.708 billion in 2022 and is expected to reach US\$ 167.883 billion by 2030. The market is estimated to register a CAGR of 4.3% from 2022 to 2030.

Infectious diseases can transfer from one person to another through direct or indirect contact. Patients must take medications with anti-infective properties to treat infectious diseases. Pathogens such as bacteria, fungi, viruses, and parasites are the primary cause of these disorders. In order to target the organism causing the sickness and implement a remedy, the host's defensive system is directly targeted. A huge geriatric population has presented a significant opportunity for the market for infectious disease therapeutics to grow in the coming years.

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products with significant medical and commercial potential for several therapeutic applications.

The following are a few of the major projects that the manufacturers have funded:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□In June 2022, GSK plc invested US\$ 1.21 billion (□1 billion) over ten years to accelerate R&D dedicated to infectious diseases. New investment supports innovation in malaria, tuberculosis, and HIV, with additional emphasis on Neglected Tropical Diseases and antimicrobial resistance.

-□In March 2022, the decision by the Canadian government to provide US\$ 48.07 million (CAD 60 million) to the Global Fund's COVID-19 Response Mechanism (C19RM) was applauded by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The additional financing will assist in providing low- and middle-income nations with life-saving diagnostic procedures, medical oxygen, and personal protective equipment (PPE).

-□In September 2021, the Biden-Harris Administration announced a US\$ 2.1 billion investment to enhance infection prevention and control initiatives in the US public health and healthcare sectors. In order to address state, municipal, and territorial health agencies and other partner organizations that deal with infectious diseases in the US, the Biden-Harris administration has made financial investments in US rescue programs through the Centers for Disease Control and Prevention (CDC).

Thus, rising focus on R&D and funding in infectious disease therapeutics drive growth in the market.

By Product, Infectious Disease Therapeutics Market-Based Insights

Based on the drug type, the infectious disease therapeutics market, by drug class, is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022; the anti-bacterial segment is likely to register the highest CAGR in the infectious disease therapeutics market from 2022-2030. Anti-viral agents are drugs approved by the US Food and Drug Administration (FDA) for treating viral infections. Anti-viral agents typically target distinct phases of the viral life cycle. Anti-viral medications can be used for prevention, treatment, suppression, or overt disease.

By Indication, Infectious Disease Therapeutics Market-Based Insights

Based on the indication, the infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2030. HIV weakens an individual's immune system by destroying important cells that fight disease and infection. Due to various factors, including sexual partners and risky behaviors, some groups of people in the US are more likely to contract HIV than others. The risk of getting an infection after surgery can rise due to growing immune system suppression by HIV. The number of patients with HIV infection has been steadily rising in recent years. The life expectancy of HIV infection and AIDS patients has significantly increased since the introduction of antiretroviral therapy (ART).

Healthcare-Associated Infections, the National Institute of Health, and the Centers for Disease Control and Prevention are a few of the major primary and secondary sources referred to while preparing the report on the infectious disease therapeutics market.

Table of Contents:

TABLE OF CONTENTS

1. Introduction
 - 1.1 The Insight Partners Research Report Guidance
 - 1.2 Market Segmentation
2. Executive Summary
 - 2.1 Key Insights
 - 2.2 Infectious Disease Therapeutics Market, by Geography (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
- 4. Infectious Disease Therapeutics Market Landscape
 - 4.1 Overview
 - 4.2 PEST Analysis
- 5. Infectious Disease Therapeutics Market - Key Market Dynamics
 - 5.1 Infectious Disease Therapeutics Market - Key Market Dynamics
 - 5.2 Market Drivers
 - 5.2.1 Rising Prevalence of Infectious Disease
 - 5.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
 - 5.3 Market Restraints
 - 5.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
 - 5.4 Market Opportunities
 - 5.4.1 Growing Opportunities in Developing Nations
 - 5.5 Future Trends
 - 5.5.1 Rising Number of Product Approvals and Launches
 - 5.6 Impact of Drivers and Restraints:
- 6. Infectious Disease Therapeutics Market - Global Market Analysis
 - 6.1 Infectious Disease Therapeutics Market Revenue (US\$ Million), 2022-2030
- 7. Infectious Disease Therapeutics Market Analysis - by Drug Class
 - 7.1 Overview
 - 7.2 Anti-Viral
 - 7.2.1 Overview
 - 7.2.2 Anti-viral: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3 Anti-bacterial
 - 7.3.1 Overview
 - 7.3.2 Anti-bacterial: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.4 Anti-fungal
 - 7.4.1 Overview
 - 7.4.2 Anti-fungal: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.5 Others
 - 7.5.1 Overview
 - 7.5.2 Others: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 8. Infectious Disease Therapeutics Market Analysis - by Indication
 - 8.1 Overview
 - 8.2 HIV
 - 8.2.1 Overview
 - 8.2.2 HIV: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 8.3 Hepatitis
 - 8.3.1 Overview
 - 8.3.2 Hepatitis: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 8.4 Tuberculosis
 - 8.4.1 Overview
 - 8.4.2 Tuberculosis: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 8.5 Influenza

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.1 Overview
- 8.5.2 Influenza: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 8.6 HPV
 - 8.6.1 Overview
 - 8.6.2 HPV: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 8.7 Others
 - 8.7.1 Overview
 - 8.7.2 Others: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 9. Infectious Disease Therapeutics Market Analysis - by Route of Administration
 - 9.1 Overview
 - 9.2 Oral
 - 9.2.1 Overview
 - 9.2.2 Oral: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 9.3 Parenteral
 - 9.3.1 Overview
 - 9.3.2 Parenteral: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 9.4 Topical
 - 9.4.1 Overview
 - 9.4.2 Topical: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 9.5 Others
 - 9.5.1 Overview
 - 9.5.2 Others: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10. Infectious Disease Therapeutics Market Analysis - by Distribution Channel
 - 10.1 Overview
 - 10.2 Hospital Pharmacies
 - 10.2.1 Overview
 - 10.2.2 Hospital Pharmacies: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.3 Retail Pharmacies
 - 10.3.1 Overview
 - 10.3.2 Retail Pharmacies: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.4 Others
 - 10.4.1 Overview
 - 10.4.2 Others: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11. Infectious Disease Therapeutics Market - Geographical Analysis
 - 11.1 North America: Infectious Disease Therapeutics Market
 - 11.1.1 Overview
 - 11.1.2 North America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.2.1 North America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 - 11.1.2.2 North America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Indication
 - 11.1.2.3 North America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Route of Administration
 - 11.1.2.4 North America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 - 11.1.3 North America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.1.3.1 North America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.1.3.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.3.2.1 Overview
 - 11.1.3.2.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.3.2.3 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.3.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
- 11.1.3.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 11.1.3.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.1.3.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.3.4.1 Overview
- 11.1.3.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.3.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.1.3.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.1.3.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.1.3.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.1.3.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.3.6.1 Overview
- 11.1.3.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.1.3.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.1.3.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.1.3.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.1.3.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.2 Europe: Infectious Disease Therapeutics Market
 - 11.2.1 Overview
 - 11.2.2 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.2.1 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 - 11.2.2.2 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Indication
 - 11.2.2.3 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Route of Administration
 - 11.2.2.4 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 - 11.2.3 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.2.3.1 Europe: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.2.3.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.2.1 Overview
 - 11.2.3.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.2.3.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.2.3.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.2.3.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
 - 11.2.3.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.4.1 Overview
 - 11.2.3.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.2.3.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.2.3.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.2.3.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
 - 11.2.3.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.6.1 Overview
 - 11.2.3.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.2.3.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.2.3.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.2.3.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.3.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.8.1 Overview
- 11.2.3.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.2.3.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.2.3.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
 - 11.2.3.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.2.3.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.10.1 Overview
- 11.2.3.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.2.3.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.2.3.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.2.3.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.2.3.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.12.1 Overview
- 11.2.3.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.2.3.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.2.3.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.2.3.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.2.3.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.3 Asia Pacific: Infectious Disease Therapeutics Market
 - 11.3.1 Overview
 - 11.3.2 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.3.2.1 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 - 11.3.2.2 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Indication
 - 11.3.2.3 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Route Of Administration
 - 11.3.2.4 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 - 11.3.3 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.3.3.1 Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.3.3.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.3.3.2.1 Overview
 - 11.3.3.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.3.3.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.3.3.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.3.3.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.3.3.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
 - 11.3.3.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.3.3.4.1 Overview
 - 11.3.3.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.3.3.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.3.3.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.3.3.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.3.3.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
 - 11.3.3.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.3.3.6.1 Overview
 - 11.3.3.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.3.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 11.3.3.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
- 11.3.3.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
- 11.3.3.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.3.3.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.3.3.8.1 Overview
- 11.3.3.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.3.3.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 11.3.3.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
- 11.3.3.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
- 11.3.3.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.3.3.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.3.3.10.1 Overview
- 11.3.3.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.3.3.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 11.3.3.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
- 11.3.3.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 11.3.3.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.3.3.12 Rest of APAC: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.3.3.12.1 Overview
- 11.3.3.13 Rest of APAC: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.3.3.13.1 Rest of APAC: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 11.3.3.13.2 Rest of APAC: Infectious Disease Therapeutics Market Breakdown, by Indication
- 11.3.3.13.3 Rest of APAC: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 11.3.3.13.4 Rest of APAC: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.4 Middle East & Africa Infectious Disease Therapeutics Market
- 11.4.1 Overview
- 11.4.2 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.4.2.1 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
- 11.4.2.2 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Indication
- 11.4.2.3 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Route of Administration
- 11.4.2.4 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.3 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
- 11.4.3.1 Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
- 11.4.3.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.4.3.2.1 Overview
- 11.4.3.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.4.3.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 11.4.3.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication
- 11.4.3.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 11.4.3.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.4.3.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.4.3.4.1 Overview
- 11.4.3.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
- 11.4.3.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 11.4.3.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.3.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 11.4.3.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.4.3.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.4.3.6.1 Overview
- 11.4.3.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.4.3.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.4.3.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.4.3.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.4.3.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.4.3.8 Rest of Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.4.3.8.1 Overview
- 11.4.3.9 Rest of Middle East and Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.4.3.9.1 Rest of Middle East and Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.4.3.9.2 Rest of Middle East and Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.4.3.9.3 Rest of Middle East and Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.4.3.9.4 Rest of Middle East and Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 11.5 South and Central America: Infectious Disease Therapeutics Market
 - 11.5.1 Overview
 - 11.5.2 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.2.1 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 - 11.5.2.2 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Indication
 - 11.5.2.3 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Route of Administration
 - 11.5.2.4 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 - 11.5.3 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.5.3.1 South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
 - 11.5.3.2 Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.3.2.1 Overview
 - 11.5.3.3 Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.3.3.1 Brazil: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.5.3.3.2 Brazil: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.5.3.3.3 Brazil: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.5.3.3.4 Brazil: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
 - 11.5.3.4 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.3.4.1 Overview
 - 11.5.3.5 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.3.5.1 Argentina: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.5.3.5.2 Argentina: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.5.3.5.3 Argentina: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
 - 11.5.3.5.4 Argentina: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
 - 11.5.3.6 Rest of South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.3.6.1 Overview
 - 11.5.3.7 Rest of South and Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)
 - 11.5.3.7.1 Rest of South and Central America: Infectious Disease Therapeutics Market Breakdown, by Drug Class
 - 11.5.3.7.2 Rest of South and Central America: Infectious Disease Therapeutics Market Breakdown, by Indication
 - 11.5.3.7.3 Rest of South and Central America: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.5.3.7.4 Rest of South and Central America: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 12. Infectious Disease Therapeutics Market-Industry Landscape
 - 12.1 Overview
 - 12.2 Growth Strategies in the Infectious Disease Therapeutics Market
 - 12.3 Inorganic Growth Strategies
 - 12.3.1 Overview
 - 12.4 Organic Growth Strategies
 - 12.4.1 Overview
- 13. Company Profiles
 - 13.1 Pfizer Inc
 - 13.1.1 Key Facts
 - 13.1.2 Business Description
 - 13.1.3 Products and Services
 - 13.1.4 Financial Overview
 - 13.1.5 SWOT Analysis
 - 13.1.6 Key Developments
 - 13.2 Gilead Sciences Inc
 - 13.2.1 Key Facts
 - 13.2.2 Business Description
 - 13.2.3 Products and Services
 - 13.2.4 Financial Overview
 - 13.2.5 SWOT Analysis
 - 13.2.6 Key Developments
 - 13.3 F. Hoffmann-La Roche Ltd
 - 13.3.1 Key Facts
 - 13.3.2 Business Description
 - 13.3.3 Products and Services
 - 13.3.4 Financial Overview
 - 13.3.5 SWOT Analysis
 - 13.3.6 Key Developments
 - 13.4 Shionogi & Co Ltd
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
 - 13.5 Bayer AG
 - 13.5.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
 - 13.6 BioCryst Pharmaceuticals Inc
 - 13.6.1 Key Facts
 - 13.6.2 Business Description

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 GSK Plc
 - 13.7.1 Key Facts
 - 13.7.2 Business Description
 - 13.7.3 Products and Services
 - 13.7.4 Financial Overview
 - 13.7.5 SWOT Analysis
 - 13.7.6 Key Developments
- 13.8 AbbVie Inc
 - 13.8.1 Key Facts
 - 13.8.2 Business Description
 - 13.8.3 Products and Services
 - 13.8.4 Financial Overview
 - 13.8.5 SWOT Analysis
 - 13.8.6 Key Developments
- 13.9 Merck & Co Inc
 - 13.9.1 Key Facts
 - 13.9.2 Business Description
 - 13.9.3 Products and Services
 - 13.9.4 Financial Overview
 - 13.9.5 SWOT Analysis
 - 13.9.6 Key Developments
- 13.10 Astellas Pharma Inc
 - 13.10.1 Key Facts
 - 13.10.2 Business Description
 - 13.10.3 Products and Services
 - 13.10.4 Financial Overview
 - 13.10.5 SWOT Analysis
 - 13.10.6 Key Developments
- 14. Appendix
 - 14.1 About The Insight Partners

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Infectious Disease Therapeutics Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti-bacterial, Anti-fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

Market Report | 2024-01-25 | 193 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$5190.00
	Site Price	\$7190.00
	Enterprise Price	\$9190.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>